InMed Pharmaceuticals (InMed Pharmaceuticals) Change In Receivables : $-0.06 Mil (TTM As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is InMed Pharmaceuticals Change In Receivables?

InMed Pharmaceuticals's change in receivables for the quarter that ended in Mar. 2024 was $0.17 Mil. It means InMed Pharmaceuticals's Accounts Receivable declined by $0.17 Mil from Dec. 2023 to Mar. 2024 .

InMed Pharmaceuticals's change in receivables for the fiscal year that ended in Jun. 2023 was $-0.22 Mil. It means InMed Pharmaceuticals's Accounts Receivable increased by $0.22 Mil from Jun. 2022 to Jun. 2023 .

InMed Pharmaceuticals's Accounts Receivable for the quarter that ended in Mar. 2024 was $0.21 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. InMed Pharmaceuticals's Days Sales Outstanding for the three months ended in Mar. 2024 was 16.18.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. InMed Pharmaceuticals's liquidation value for the three months ended in Mar. 2024 was $6.10 Mil.

InMed Pharmaceuticals Change In Receivables Historical Data

The historical data trend for InMed Pharmaceuticals's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InMed Pharmaceuticals Change In Receivables Chart

InMed Pharmaceuticals Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Change In Receivables

Get a 7-Day Free Trial

-0.02

0.02

0.04

-0.04

-0.22

InMed Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															-0.09	-0.11	0.10	-0.21	0.17

InMed Pharmaceuticals Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.06 Mil.

InMed Pharmaceuticals (NAS:INM) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

InMed Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.208	/	1.173	*	91
=	16.18

2. In Ben Graham's calculation of liquidation value, InMed Pharmaceuticals's accounts receivable are only considered to be worth 75% of book value:

InMed Pharmaceuticals's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	7.601	-	2.254	+	0.75 * 0.208	+	0.5 * 1.194
=	6.10

InMed Pharmaceuticals Change In Receivables Related Terms

Thank you for viewing the detailed overview of InMed Pharmaceuticals's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

InMed Pharmaceuticals (InMed Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InMed Pharmaceuticals Inc (NAS:INM) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

MWG0:Germany

Address

815 West Hastings Street, Suite 310, Vancouver, BC, CAN, V6C 1B4

Website

https://www.inmedpharma.com

InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.

Executives

Jonathan Tegge	officer: Interim CFO	217 W. MAIN STREET, SOMERVILLE NJ 08876
Sarah Li	officer: VP, Accounting and Controller	310-815 WEST HASTINGS ST., VANCOUVER Z4 V6C1B4
Nicole Lemerond	director	3 MURRAY HILL ROAD, SCARSDALE NY 10583
Bryan T Baldasare	director	3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Eric A Adams	director, officer: President & CEO	C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4
Brenda Edwards	officer: Interim CFO	111-1232 JOHNSON ST., COQUITLAM A1 V3B 4T2
Janet P Grove	director	510 WEST GEORGIA STREET, SUITE 1800, VANCOUVER A1 V5T 4T5
Bruce Colwill	officer: CFO	C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4
Shane Aaron Johnson	officer: SVP & GM of BayMedica LLC	930 TAHOE BLVD., SUITE 802-433, INCLINE VILLAGE NV 89451
Adam D. Cutler	director	9301 AMBERGLEN BOULEVARD, SUITE 100, C/O MOLECULAR TEMPLATES, INC., AUSTIN TX 78729
William J Garner	director	875 MAHLER ROAD, SUITE 235, BURLINGAME CA 94010
Catherine Sazdanoff	director	3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Eric C Hsu	officer: Sr. VP, Pre-Clinical Res/Dev	C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4
Michael Woudenberg	officer: VP, Chem/Manufacturing/Control	C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4
Mancini Alexandra Diane Janet	officer: Sr VP, Clinical Reg Affairs	C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4